Sign Out
Should not be administered to patients with haematopoietic disorders such as neutropenia or thrombocytopenia, hemorrhagic diathesis or other haemorrhagic disorders associated by a prolonged bleeding time or conditions with an increased risk of bleeding such as gastrointestinal ulcers, acute cerebral hemorrhage or severe liver dysfunction.
Full blood counts should be performed before starting treatment and every two (2) weeks during first three months of therapy. If discontinued, a full blood count should be performed within (2) weeks of stopping treatment. Consideration should be given to stopping Clopidogrel therapy 10-14 days before elective surgery.
Continue with Google